Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes
Diabetes/Metabolism Research and Reviews · 2024-02 · 40 (2)
DOI: 10.1002/dmrr.3777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 20.02.2024. Verfasst von A Emile J Hendriks und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/Aim Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta‐cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody‐positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis.
Methods
Expert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow‐up strategies.
Results
The guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3‐monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented.
Conclusions
As type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, University of Cambridge, Cambridge, UK.
- Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
- Department of Paediatrics, University of Oxford, Oxford, UK.
- Technische Universität Dresden, Center for Regenerative Therapies Dresden, Dresden, Germany.
- German Center for Diabetes Research (DZD e.V.), Munich, Germany.
ORCID-Profile: A Emile J Hendriks
Zitieren
APA
Hendriks, A. E. J., Marcovecchio, M. L., Besser, R. E. J., Bonifacio, E., Casteels, K., Elding Larsson, H., Gemulla, G., Lundgren, M., Kordonouri, O., Mallone, R., Pociot, F., Szypowska, A., Toppari, J., Berge, T. V. D., Ziegler, A. G., Mathieu, C., Achenbach, P., & INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group (2024). Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes/Metabolism Research and Reviews, 40(2). https://doi.org/10.1002/dmrr.3777
Vancouver
Hendriks AEJ, Marcovecchio ML, Besser REJ, Bonifacio E, Casteels K, Elding Larsson H, et al. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2024;40(2). doi:10.1002/dmrr.3777
BibTeX
@article{Hendriks2024,
author = {Hendriks, A Emile J and Marcovecchio, M Loredana and Besser, Rachel E J and Bonifacio, Ezio and Casteels, Kristina and Elding Larsson, Helena and Gemulla, Gita and Lundgren, Markus and Kordonouri, Olga and Mallone, Roberto and Pociot, Flemming and Szypowska, Agnieszka and Toppari, Jorma and Berge, Thekla von dem and Ziegler, Anette G and Mathieu, Chantal and Achenbach, Peter and INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group, INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group},
title = {Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2024},
volume = {40},
number = {2},
doi = {10.1002/dmrr.3777}
}
EUVIMED